Potential Anti-Cancer Benefits of GLP-1 Receptor Agonists Beyond Weight Loss
New research indicates that GLP-1 receptor agonists, used for diabetes and weight loss, may also provide significant protection against obesity-related cancers beyond their metabolic effects. The study compares these medications to bariatric surgery, revealing potential anti-cancer benefits that merit further investigation.
Recent research presented at the European Congress on Obesity and published in eClinicalMedicine suggests that first-generation GLP-1 receptor agonists (GLP-1 RAs), commonly used for managing type 2 diabetes and obesity, may offer protective effects against obesity-related cancers beyond their role in weight loss. Studies comparing GLP-1 RAs such as liraglutide and exenatide with bariatric surgery have shown that these medications can reduce the risk of cancers associated with obesity, including postmenopausal breast, colorectal, uterine, and other cancers.
In an extensive observational study involving over 6,300 patients with obesity and type 2 diabetes from Israel, researchers followed individuals treated either with GLP-1 RAs or bariatric surgery for an average of 7.5 years. Results indicated that the incidence of obesity-related cancers was similar between the two groups, despite bariatric surgery's superior weight reduction. Notably, after adjusting for weight loss differences, GLP-1 RAs demonstrated a 41% greater effectiveness in reducing cancer risk compared to surgery, hinting at mechanisms beyond weight control.
Dr. Yael Wolff Sagy explained that their findings point to potential anti-cancer properties of GLP-1 RAs, possibly related to reducing inflammation and other metabolic pathways. Although the precise actions of these medications remain to be fully understood, this research underscores their promising role in cancer prevention.
While first-generation GLP-1 RAs are well established for their weight-loss and metabolic benefits, ongoing studies are exploring whether newer, more potent formulations might further enhance cancer protective effects. However, further randomized clinical trials are necessary to confirm these findings and uncover the underlying mechanisms.
This study highlights the potential for GLP-1 receptor agonists to serve as a valuable tool in reducing obesity-related cancer risks, adding to their established benefits for diabetes and weight management.
Source: https://medicalxpress.com/news/2025-05-glp-receptor-agonists-anti-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Collaborative AI and Medical Research Aim to Predict and Prevent Persistent Post-Surgical Pain
Advances in machine learning are helping clinicians predict and prevent persistent post-surgical pain by analyzing patient data and assessing prediction uncertainty, offering new hope for personalized pain management.
Employment Can Boost Recovery in Individuals with Alcohol Use Disorder
Work and employment support significantly improve recovery outcomes for individuals treating alcohol use disorder, reducing drinking frequency and enhancing quality of life.
Genetic Inheritance May Predict Resistance to Immunotherapy in Advanced Skin Cancer
New research identifies a mitochondrial DNA mutation that predicts resistance to immunotherapy in patients with advanced melanoma, paving the way for personalized cancer treatments.
Research Reveals Fatty Liver Is Common in People with Type 2 Diabetes, But Severe Liver Damage Remains Rare
New research indicates that fatty liver disease is highly prevalent among individuals with type 2 diabetes, yet severe liver damage remains uncommon. Early detection and weight loss are key to prevention.